AFT Pharmaceuticals (AFP) Stock Overview

Develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. More details

AFP fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 76.3% below our estimate of its fair value

Earnings are forecast to grow 25.67% per year

Risk Analysis

Shares are highly illiquid

AFP Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Hoth Therapeutics

100% Patient Improvement in trial puts this $16M Biotech on the radar

Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.

132

US$5.3

70.2% undervalued

Jolt_Communications Fair Value

Revenue growth

N/A

Profit Margin

30%

Future PE

20x

Share price in 2030

US$0

AFT Pharmaceuticals Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for AFT Pharmaceuticals
Historical stock prices
Current Share Price	NZ$2.51
52 Week High	NZ$2.76
52 Week Low	NZ$2.50
Beta	0.29
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-47.71%
Change since IPO	-30.28%

Recent updates

Shareholder Returns

	AFP	AU Pharmaceuticals	AU Market
7D	0%	16.0%	2.3%
1Y	n/a	-7.7%	10.1%

Return vs Industry: Insufficient data to determine how AFP performed against the Australian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how AFP performed against the Australian Market.

Price Volatility

Is AFP's price volatile compared to industry and market?
AFP volatility
AFP Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	11.5%
Market Average Movement	9.2%
10% most volatile stocks in AU Market	19.7%
10% least volatile stocks in AU Market	3.4%

Stable Share Price: AFP's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: Insufficient data to determine AFP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1997	119	Hartley Atkinson	www.aftpharm.com

AFT Pharmaceuticals Limited, together with its subsidiaries, develops, markets, and distributes pharmaceutical products in New Zealand, Australia, Asia, and internationally. The company offers patented, branded, and generic drugs; and products for use in the areas of allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, vitamins, supplements, gastrointestinal, dermatology, and hospital. It has a research and development collaboration with Belgium’s Hyloris Pharmaceuticals to develop a novel innovative injectable iron deficiency therapy.

AFT Pharmaceuticals Limited Fundamentals Summary

How do AFT Pharmaceuticals's earnings and revenue compare to its market cap?
AFP fundamental statistics
Market cap	AU$258.47m
Earnings (TTM)	AU$10.57m
Revenue (TTM)	AU$183.77m

24.5x

P/E Ratio

1.4x

P/S Ratio

Is AFP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AFP income statement (TTM)
Revenue	NZ$208.02m
Cost of Revenue	NZ$116.31m
Gross Profit	NZ$91.71m
Other Expenses	NZ$79.75m
Earnings	NZ$11.96m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	0.11
Gross Margin	44.09%
Net Profit Margin	5.75%
Debt/Equity Ratio	27.5%

How did AFP perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

16%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/10/04 05:32
End of Day Share Price	2025/09/25 00:00
Earnings	2025/03/31
Annual Earnings	2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AFT Pharmaceuticals Limited is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Hester	Bell Potter
Jack Crowley	Credit Suisse
Jyoti Prakash	Edison Investment Research

AFT Pharmaceuticals LimitedCHIA:AFP Stock Report